Global Antidiarrheal Drugs Market

Antidiarrheal Drugs Comprehensive Study by Type (OTC Drugs, Prescription Drugs, Others), Application (Adults, Children), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Drug Class (Mucosal Protectants and Absorbents, Motility Modifying Drugs) Players and Region - Global Market Outlook to 2026

Antidiarrheal Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antidiarrheal Drugs Market Scope?
Antidiarrheal drugs medication is used to treat sudden diarrhea and possess the mechanism of slowing down the movement of the gut. This decreases the number of bowel movements and makes the stool less watery. This helps to reduce the number of bowel movements and also makes the stools less watery. It is referred to as chronic diarrhea if it lasts for more than two weeks. Various causes of diarrhea can be a virus such as a rotavirus, hepatitis, bacteria such as E. coli, Shigella, and parasites such as those causing amoebiasis and giardiasis. Anti diarrheal drugs also help in treating ongoing diarrhea in people with inflammatory bowel disease.

Influencing Trend:
Increase in the Cases of Diarrhea Patients across the Globe

Market Growth Drivers:
The rise in Diarrheal Disease and Increasing Investment in Healthcare Infrastructure by various Government

Challenges:
Strict Regulation Regarding Drugs

Restraints:
Side effects of Anti-Diarrheal drugs

Opportunities:
Massive Demand for Antidiarrheal Medicines in Emerging Economies as well as in Underdeveloped Countries

The Antidiarrheal Drugs market study is being classified by Type (OTC Drugs, Prescription Drugs and Others), by Application and major geographies with country level break-up.

The Players having a strong hold in the market are Johnson & Johnson, Novartis International AG, GlaxoSmithKline plc, and Proctor & Gamble. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Antidiarrheal Drugs market throughout the predicted period.

Johnson & Johnson (United States), Novartis International AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Proctor & Gamble (United States), Pfizer (United States), Actelion (Switzerland), Perrigo (Ireland), Sanofi Aventis (France), Merck & Co. (United States) and Bayer AG (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Glenmark Pharmaceuticals (India) and Lupin (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Antidiarrheal Drugs market by Type, Application and Region.

On the basis of geography, the market of Antidiarrheal Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In December 2019, Sanofi Aventis and Regeneron Pharmaceuticals, Inc have announced their intent to simplify their antibody collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement.
In February 2020, Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris Seasonal Allergic Rhinitis Spray in the United States.


Key Target Audience
Antidiarrheal Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Antidiarrheal Drugs Market Study: Important Years
AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Antidiarrheal Drugs Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Antidiarrheal Drugs industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • OTC Drugs
  • Prescription Drugs
  • Others
By Application
  • Adults
  • Children
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
  • Others

By Drug Class
  • Mucosal Protectants and Absorbents
  • Motility Modifying Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in Diarrheal Disease
      • 3.2.2. Increasing Investment in Healthcare Infrastructure by various Government
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulation Regarding Drugs
    • 3.4. Market Trends
      • 3.4.1. Increase in the Cases of Diarrhea Patients across the Globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antidiarrheal Drugs, by Type, Application, Distribution Channel, Drug Class and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Antidiarrheal Drugs (Value)
      • 5.2.1. Global Antidiarrheal Drugs by: Type (Value)
        • 5.2.1.1. OTC Drugs
        • 5.2.1.2. Prescription Drugs
        • 5.2.1.3. Others
      • 5.2.2. Global Antidiarrheal Drugs by: Application (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children
      • 5.2.3. Global Antidiarrheal Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Antidiarrheal Drugs by: Drug Class (Value)
        • 5.2.4.1. Mucosal Protectants and Absorbents
        • 5.2.4.2. Motility Modifying Drugs
      • 5.2.5. Global Antidiarrheal Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antidiarrheal Drugs (Price)
      • 5.3.1. Global Antidiarrheal Drugs by: Type (Price)
  • 6. Antidiarrheal Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Proctor & Gamble (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Actelion (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Perrigo (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi Aventis (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antidiarrheal Drugs Sale, by Type, Application, Distribution Channel, Drug Class and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Antidiarrheal Drugs (Value)
      • 7.2.1. Global Antidiarrheal Drugs by: Type (Value)
        • 7.2.1.1. OTC Drugs
        • 7.2.1.2. Prescription Drugs
        • 7.2.1.3. Others
      • 7.2.2. Global Antidiarrheal Drugs by: Application (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children
      • 7.2.3. Global Antidiarrheal Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Antidiarrheal Drugs by: Drug Class (Value)
        • 7.2.4.1. Mucosal Protectants and Absorbents
        • 7.2.4.2. Motility Modifying Drugs
      • 7.2.5. Global Antidiarrheal Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antidiarrheal Drugs (Price)
      • 7.3.1. Global Antidiarrheal Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antidiarrheal Drugs: by Type(USD Million)
  • Table 2. Antidiarrheal Drugs OTC Drugs , by Region USD Million (2016-2021)
  • Table 3. Antidiarrheal Drugs Prescription Drugs , by Region USD Million (2016-2021)
  • Table 4. Antidiarrheal Drugs Others , by Region USD Million (2016-2021)
  • Table 5. Antidiarrheal Drugs: by Application(USD Million)
  • Table 6. Antidiarrheal Drugs Adults , by Region USD Million (2016-2021)
  • Table 7. Antidiarrheal Drugs Children , by Region USD Million (2016-2021)
  • Table 8. Antidiarrheal Drugs: by Distribution Channel(USD Million)
  • Table 9. Antidiarrheal Drugs Hospital Pharmacy , by Region USD Million (2016-2021)
  • Table 10. Antidiarrheal Drugs Retail Pharmacy , by Region USD Million (2016-2021)
  • Table 11. Antidiarrheal Drugs Online , by Region USD Million (2016-2021)
  • Table 12. Antidiarrheal Drugs Others , by Region USD Million (2016-2021)
  • Table 13. Antidiarrheal Drugs: by Drug Class(USD Million)
  • Table 14. Antidiarrheal Drugs Mucosal Protectants and Absorbents , by Region USD Million (2016-2021)
  • Table 15. Antidiarrheal Drugs Motility Modifying Drugs , by Region USD Million (2016-2021)
  • Table 16. South America Antidiarrheal Drugs, by Country USD Million (2016-2021)
  • Table 17. South America Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 18. South America Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 19. South America Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 20. South America Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 21. Brazil Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 22. Brazil Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 23. Brazil Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 24. Brazil Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 25. Argentina Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 26. Argentina Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 27. Argentina Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 28. Argentina Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 29. Rest of South America Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 30. Rest of South America Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 31. Rest of South America Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 32. Rest of South America Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 33. Asia Pacific Antidiarrheal Drugs, by Country USD Million (2016-2021)
  • Table 34. Asia Pacific Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 35. Asia Pacific Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 36. Asia Pacific Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 37. Asia Pacific Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 38. China Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 39. China Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 40. China Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 41. China Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 42. Japan Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 43. Japan Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 44. Japan Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 45. Japan Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 46. India Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 47. India Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 48. India Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 49. India Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 50. South Korea Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 51. South Korea Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 52. South Korea Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 53. South Korea Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 54. Taiwan Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 55. Taiwan Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 56. Taiwan Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 57. Taiwan Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 58. Australia Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 59. Australia Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 60. Australia Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 61. Australia Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 66. Europe Antidiarrheal Drugs, by Country USD Million (2016-2021)
  • Table 67. Europe Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 68. Europe Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 69. Europe Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 70. Europe Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 71. Germany Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 72. Germany Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 73. Germany Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 74. Germany Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 75. France Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 76. France Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 77. France Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 78. France Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 79. Italy Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 80. Italy Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 81. Italy Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 82. Italy Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 83. United Kingdom Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 84. United Kingdom Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 85. United Kingdom Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 86. United Kingdom Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 87. Netherlands Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 88. Netherlands Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 89. Netherlands Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 90. Netherlands Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 91. Rest of Europe Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 93. Rest of Europe Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 94. Rest of Europe Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 95. MEA Antidiarrheal Drugs, by Country USD Million (2016-2021)
  • Table 96. MEA Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 97. MEA Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 98. MEA Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 99. MEA Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 100. Middle East Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 101. Middle East Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 102. Middle East Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 103. Middle East Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 104. Africa Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 105. Africa Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 106. Africa Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 107. Africa Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 108. North America Antidiarrheal Drugs, by Country USD Million (2016-2021)
  • Table 109. North America Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 110. North America Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 111. North America Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 112. North America Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 113. United States Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 114. United States Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 115. United States Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 116. United States Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 117. Canada Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 118. Canada Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 119. Canada Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 120. Canada Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 121. Mexico Antidiarrheal Drugs, by Type USD Million (2016-2021)
  • Table 122. Mexico Antidiarrheal Drugs, by Application USD Million (2016-2021)
  • Table 123. Mexico Antidiarrheal Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 124. Mexico Antidiarrheal Drugs, by Drug Class USD Million (2016-2021)
  • Table 125. Antidiarrheal Drugs: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Antidiarrheal Drugs: by Type(USD Million)
  • Table 137. Antidiarrheal Drugs OTC Drugs , by Region USD Million (2022-2027)
  • Table 138. Antidiarrheal Drugs Prescription Drugs , by Region USD Million (2022-2027)
  • Table 139. Antidiarrheal Drugs Others , by Region USD Million (2022-2027)
  • Table 140. Antidiarrheal Drugs: by Application(USD Million)
  • Table 141. Antidiarrheal Drugs Adults , by Region USD Million (2022-2027)
  • Table 142. Antidiarrheal Drugs Children , by Region USD Million (2022-2027)
  • Table 143. Antidiarrheal Drugs: by Distribution Channel(USD Million)
  • Table 144. Antidiarrheal Drugs Hospital Pharmacy , by Region USD Million (2022-2027)
  • Table 145. Antidiarrheal Drugs Retail Pharmacy , by Region USD Million (2022-2027)
  • Table 146. Antidiarrheal Drugs Online , by Region USD Million (2022-2027)
  • Table 147. Antidiarrheal Drugs Others , by Region USD Million (2022-2027)
  • Table 148. Antidiarrheal Drugs: by Drug Class(USD Million)
  • Table 149. Antidiarrheal Drugs Mucosal Protectants and Absorbents , by Region USD Million (2022-2027)
  • Table 150. Antidiarrheal Drugs Motility Modifying Drugs , by Region USD Million (2022-2027)
  • Table 151. South America Antidiarrheal Drugs, by Country USD Million (2022-2027)
  • Table 152. South America Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 153. South America Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 154. South America Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 155. South America Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 156. Brazil Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 157. Brazil Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 158. Brazil Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 159. Brazil Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 160. Argentina Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 161. Argentina Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 162. Argentina Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 163. Argentina Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 164. Rest of South America Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 165. Rest of South America Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 166. Rest of South America Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 167. Rest of South America Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 168. Asia Pacific Antidiarrheal Drugs, by Country USD Million (2022-2027)
  • Table 169. Asia Pacific Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 170. Asia Pacific Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 171. Asia Pacific Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 172. Asia Pacific Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 173. China Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 174. China Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 175. China Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 176. China Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 177. Japan Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 178. Japan Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 179. Japan Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 180. Japan Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 181. India Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 182. India Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 183. India Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 184. India Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 185. South Korea Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 186. South Korea Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 187. South Korea Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 188. South Korea Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 189. Taiwan Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 190. Taiwan Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 191. Taiwan Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 192. Taiwan Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 193. Australia Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 194. Australia Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 195. Australia Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 196. Australia Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 201. Europe Antidiarrheal Drugs, by Country USD Million (2022-2027)
  • Table 202. Europe Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 203. Europe Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 204. Europe Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 205. Europe Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 206. Germany Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 207. Germany Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 208. Germany Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 209. Germany Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 210. France Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 211. France Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 212. France Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 213. France Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 214. Italy Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 215. Italy Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 216. Italy Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 217. Italy Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 218. United Kingdom Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 219. United Kingdom Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 220. United Kingdom Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 221. United Kingdom Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 222. Netherlands Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 223. Netherlands Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 224. Netherlands Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 225. Netherlands Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 226. Rest of Europe Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 227. Rest of Europe Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 228. Rest of Europe Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 229. Rest of Europe Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 230. MEA Antidiarrheal Drugs, by Country USD Million (2022-2027)
  • Table 231. MEA Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 232. MEA Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 233. MEA Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 234. MEA Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 235. Middle East Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 236. Middle East Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 237. Middle East Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 238. Middle East Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 239. Africa Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 240. Africa Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 241. Africa Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 242. Africa Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 243. North America Antidiarrheal Drugs, by Country USD Million (2022-2027)
  • Table 244. North America Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 245. North America Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 246. North America Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 247. North America Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 248. United States Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 249. United States Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 250. United States Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 251. United States Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 252. Canada Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 253. Canada Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 254. Canada Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 255. Canada Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 256. Mexico Antidiarrheal Drugs, by Type USD Million (2022-2027)
  • Table 257. Mexico Antidiarrheal Drugs, by Application USD Million (2022-2027)
  • Table 258. Mexico Antidiarrheal Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 259. Mexico Antidiarrheal Drugs, by Drug Class USD Million (2022-2027)
  • Table 260. Antidiarrheal Drugs: by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antidiarrheal Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Antidiarrheal Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Antidiarrheal Drugs: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Antidiarrheal Drugs: by Drug Class USD Million (2016-2021)
  • Figure 8. South America Antidiarrheal Drugs Share (%), by Country
  • Figure 9. Asia Pacific Antidiarrheal Drugs Share (%), by Country
  • Figure 10. Europe Antidiarrheal Drugs Share (%), by Country
  • Figure 11. MEA Antidiarrheal Drugs Share (%), by Country
  • Figure 12. North America Antidiarrheal Drugs Share (%), by Country
  • Figure 13. Global Antidiarrheal Drugs: by Type USD/Units (2016-2021)
  • Figure 14. Global Antidiarrheal Drugs share by Players 2021 (%)
  • Figure 15. Global Antidiarrheal Drugs share by Players (Top 3) 2021(%)
  • Figure 16. Global Antidiarrheal Drugs share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 20. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2021
  • Figure 24. Proctor & Gamble (United States) Revenue, Net Income and Gross profit
  • Figure 25. Proctor & Gamble (United States) Revenue: by Geography 2021
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2021
  • Figure 28. Actelion (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Actelion (Switzerland) Revenue: by Geography 2021
  • Figure 30. Perrigo (Ireland) Revenue, Net Income and Gross profit
  • Figure 31. Perrigo (Ireland) Revenue: by Geography 2021
  • Figure 32. Sanofi Aventis (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi Aventis (France) Revenue: by Geography 2021
  • Figure 34. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co. (United States) Revenue: by Geography 2021
  • Figure 36. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 38. Global Antidiarrheal Drugs: by Type USD Million (2022-2027)
  • Figure 39. Global Antidiarrheal Drugs: by Application USD Million (2022-2027)
  • Figure 40. Global Antidiarrheal Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 41. Global Antidiarrheal Drugs: by Drug Class USD Million (2022-2027)
  • Figure 42. South America Antidiarrheal Drugs Share (%), by Country
  • Figure 43. Asia Pacific Antidiarrheal Drugs Share (%), by Country
  • Figure 44. Europe Antidiarrheal Drugs Share (%), by Country
  • Figure 45. MEA Antidiarrheal Drugs Share (%), by Country
  • Figure 46. North America Antidiarrheal Drugs Share (%), by Country
  • Figure 47. Global Antidiarrheal Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Novartis International AG (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Proctor & Gamble (United States)
  • Pfizer (United States)
  • Actelion (Switzerland)
  • Perrigo (Ireland)
  • Sanofi Aventis (France)
  • Merck & Co. (United States)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Glenmark Pharmaceuticals (India) , Lupin (India)
Select User Access Type

Key Highlights of Report


Feb 2022 247 Pages 66 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antidiarrheal Drugs Market Quantitative research analysis
Global Antidiarrheal Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Antidiarrheal Drugs market are Johnson & Johnson (United States), Novartis International AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Proctor & Gamble (United States), Pfizer (United States), Actelion (Switzerland), Perrigo (Ireland), Sanofi Aventis (France), Merck & Co. (United States) and Bayer AG (Germany).
In this highly competitive & fast evolving Antidiarrheal Drugs industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Adults and Children are the potential customers of Antidiarrheal Drugs industry.

Know More About Global Antidiarrheal Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Mental Illness Drugs Comprehensive Study by Type (Antipsychotics, Antidepressants, Antianxiety (anxiolytics), Anti-seizure medications), Application (Hospital, Clinic, Drugstore), Distribution Channe...
$ 3750
Fish Vaccine Comprehensive Study by Type (Live, Inactivated, Subunit, DNA, Others), Application (Body in learning how to protect it from viruses), Administration (Oral, Immersion, Injected), Fish (Sa...
$ 3500
Dermatophytosis Drugs Comprehensive Study by Application (Superficial Antifungal Infections, Systemic Antifungal Infections), Route of Administration (Oral, Topical, Parenteral), Form (Powder, Ointme...
$ 3350
Pharmaceutical and Medicinal Herbal Extracts Comprehensive Study by Type (Capsule, Tablet, Powder, Others), Application (Treatment, Massage, Medicines), End-Use (Traditional Chinese Medicine, Western...
$ 3350
Clopidogrel Bisulfate Comprehensive Study by Application (Heart Attacks, Strokes, Peripheral Arterial Diseases), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Ret...
$ 3350
Gemcitabine Comprehensive Study by Application (Pancreas Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Soft-Tissue Sarcoma, Metastatic Breast Cancer, Ovarian Cancer), Distribution Channel (Hosp...
$ 3450